Sponsor stopped the study

To characterize using a participant centered decentralized (at home) study featuring wearable technology and telemedicine to study disease change over time in patients with PD caused by the G2019S mutation in the LRRK2 gene and to identify a clinical endpoint(s) for disease modifying experimental therapy trials.

Part A Inclusion Criteria (Healthy Volunteers)

Individuals eligible to participate in Part A of this study will meet all the following criteria:

1. Willing and able to provide informed consent after the nature of the study has been explained
2. 18-35 years of age inclusive at Screening (sub cohort A1) or 65-80 years of age inclusive at Screening (sub cohort A2)
3. Willing and able to comply with all study procedures
4. Sub cohort A3 participants must match the age ± 0.5 years and sex of match participant in Part B
5. Participant must be healthy as per the investigator's assessment with no underlying clinically significant diseases (participants with hypertension, diabetes, hypercholesterolemia, and other chronic diseases associated with aging but not thought to interfere with the performance of the mTUG or other study measures may be allowed after consultation with the Medical Monitor)
6. Participant must be able to use the Technology as described in the protocol
7. Have access to a minimum indoor space of 6 meters by 2 meters (or approximately 20 feet by 7 feet) to carry out the mTUG
8. Agree to retain the same level of activity throughout the study and not have plans to stop/start or increase or decrease any exercise programs
9. Have reliable access to working WiFi internet or willingness to use a provided cellular internet connection device
10. Agree to refrain from all alcohol and cannabinoid products within 24 hours prior to performing the mTUG assessment (i.e., three non consecutive days during study Week two, and Weeks two and three of the run in period)

Part A Exclusion Criteria (Healthy Volunteers)

Individuals who meet any of the following exclusion criteria will not be eligible to participate in the study:

1. History of mobility, gait, or ambulation problems (defined as mobility limitations that impact walking on a daily basis)
2. History of neurological disease
3. Any elective surgery planned during the study duration, approximately 12-15 months from Screening
4. History of significant head injury within the past 5 years (head injury with loss of consciousness or requiring greater than 24 hours in hospital in relation to head injury)
5. History of alcohol use disorder or other substance abuse disorder (excluding tobacco use), according to the Diagnostic and Statistical Manual of Mental Disorders 5th Edition (DSM-5) in the past 10 years
6. Body Mass Index (BMI) (calculated from self reported height and weight) of greater than 35
7. Pregnant or planning to become pregnant in the next 24 months
8. Has a concurrent disease or condition that, in the view of the investigator, places the subject at high risk of poor treatment compliance or of not completing the study, or would interfere with study participation or would affect safety

Part B Inclusion Criteria (PD Patients)

Individuals eligible to participate in Part B of this study must meet all the following criteria:

1. Willing and able to provide informed consent after the nature of the study has been explained
2. Willing and able to comply with all study procedures
3. Have confirmed diagnosis of PD documented in medical records according to UK Brain Bank criteria
4. Confirmed G2019S mutation(s) in the LRRK2 gene either by evidence recorded in medical record with report from accredited laboratory, or through another accredited genetic testing program, or other partner laboratory. Up to 10 participants with homozygous mutations may be enrolled in addition to the 60 participants with heterozygous mutation
5. Hoehn and Yahr Scale Score 1-3
6. Physically and cognitively able to complete protocol specified tasks independently or with some assistance
7. If assistance is required for completion of tasks (e.g., help with the Technology), a caregiver or volunteer must be fully available to assist the participant for the duration of the study
8. Ability to complete the mTUG without the use of a cane or walker and without a personal assistant
9. Ability to complete the mTUG which is not impacted by comorbidities (e.g., participant should not have underlying, clinically significant cardiac or respiratory disease, or musculoskeletal disease). Non-progressive diseases of these organ systems must be approved by the Medical Monitor prior to enrollment; for example, mild to moderate osteoarthritis may be allowable
10. Have access to a minimum indoor space of 6 meters by 2 meters (or approximately 20 feet by 7 feet) to carry out the mTUG
11. A helper or participant is required to be present during the performance of mTUG, if the participant has had more than one fall in the past 12 months
12. The participant's general health status is acceptable for participation in the study (per their physician)
13. Working WiFi internet or willing to use a provided cellular internet connection device
14. Participant must agree to refrain from all alcohol and cannabinoid products within 24 hours prior to performing the mTUG (i.e., three non consecutive days during study Week two, and Weeks two and four of the run in period)

Part B Exclusion Criteria (PD Patients)

Individuals who meet any of the following exclusion criteria will not be eligible to participate in the study:

1. Any mobility, gait, or ambulation problems other than those related to PD
2. Any deep brain stimulation in situ or planned during the study duration, approximately 12-15 months from Screening
3. Any planned changes in physiotherapy or exercise therapy
4. Planned initiation of, or changes in, cognitive behavioral therapy
5. Any elective planned surgery during the study duration, approximately 12-15 months from Screening
6. History of significant head injury within the past 5 years (head injury with loss of consciousness or requiring greater than 24 hours in hospital in relation to head injury)
7. History of frequent falls (classified as one fall every 1 month)
8. Any other genetic PD causing mutations, for example, a pathogenic GBA mutation
9. History of alcohol use disorder or other substance abuse disorder (excluding tobacco use), according to the DSM-5 in the past 10 years
10. Any other serious concomitant diseases unrelated to PD (e.g., other neurological diseases of any kind, renal failure, liver failure, active cancer)
11. BMI (calculated from self reported height and weight) of greater than 35
12. Pregnant or planning to become pregnant in the next 24 months
13. Has a concurrent disease or condition that, in the view of the investigator, places the subject at high risk of poor treatment compliance or of not completing the study, or would interfere with study participation or would affect safety

• Part A (Healthy Volunteers): Healthy participants aged 18-80 years of age
• Part B (Patients with Parkinson Disease): Participants with PD caused by the G2019S pathogenic mutation of the LRRK2 gene